190 related articles for article (PubMed ID: 20855467)
1. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
Bedikian AY; DeConti RC; Conry R; Agarwala S; Papadopoulos N; Kim KB; Ernstoff M
Ann Oncol; 2011 Apr; 22(4):787-793. PubMed ID: 20855467
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Hersh EM; Del Vecchio M; Brown MP; Kefford R; Loquai C; Testori A; Bhatia S; Gutzmer R; Conry R; Haydon A; Robert C; Ernst S; Homsi J; Grob JJ; Kendra K; Agarwala SS; Li M; Clawson A; Brachmann C; Karnoub M; Elias I; Renschler MF; Hauschild A
Ann Oncol; 2015 Nov; 26(11):2267-74. PubMed ID: 26410620
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
Homsi J; Bedikian AY; Papadopoulos NE; Kim KB; Hwu WJ; Mahoney SL; Hwu P
Melanoma Res; 2010 Dec; 20(6):507-10. PubMed ID: 20881508
[TBL] [Abstract][Full Text] [Related]
6. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
9. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
Jones RJ; Hawkins RE; Eatock MM; Ferry DR; Eskens FA; Wilke H; Evans TR
Cancer Chemother Pharmacol; 2008 Mar; 61(3):435-41. PubMed ID: 17440725
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
11. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Patel PM; Suciu S; Mortier L; Kruit WH; Robert C; Schadendorf D; Trefzer U; Punt CJ; Dummer R; Davidson N; Becker J; Conry R; Thompson JA; Hwu WJ; Engelen K; Agarwala SS; Keilholz U; Eggermont AM; Spatz A;
Eur J Cancer; 2011 Jul; 47(10):1476-83. PubMed ID: 21600759
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Feun LG; Savaraj N; Hurley J; Marini A
Cancer Invest; 2002; 20(3):357-61. PubMed ID: 12025231
[TBL] [Abstract][Full Text] [Related]
13. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
Carvajal RD; Piperno-Neumann S; Kapiteijn E; Chapman PB; Frank S; Joshua AM; Piulats JM; Wolter P; Cocquyt V; Chmielowski B; Evans TRJ; Gastaud L; Linette G; Berking C; Schachter J; Rodrigues MJ; Shoushtari AN; Clemett D; Ghiorghiu D; Mariani G; Spratt S; Lovick S; Barker P; Kilgour E; Lai Z; Schwartz GK; Nathan P
J Clin Oncol; 2018 Apr; 36(12):1232-1239. PubMed ID: 29528792
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
17. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Lee CK; Jung M; Choi HJ; Kim HR; Kim HS; Roh MR; Ahn JB; Chung HC; Heo SJ; Rha SY; Shin SJ
Cancer Res Treat; 2015 Oct; 47(4):781-9. PubMed ID: 25687848
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
[TBL] [Abstract][Full Text] [Related]
19. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
[TBL] [Abstract][Full Text] [Related]
20. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.
Payne M; Ellis P; Dunlop D; Ranson M; Danson S; Schacter L; Talbot D
J Thorac Oncol; 2006 Nov; 1(9):984-90. PubMed ID: 17409983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
